IMMX Stock Alert: The Massive FDA Win That Has Immix Biopharma Blasting Higher Today

Immix Biopharma (NASDAQ:IMMX) stock is taking off on Monday thanks to a Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA).

colorful pills and vials sitting on a table representing IMMX stock.

Source: Bukhta Yurii /

This RPD designation covers IMX-110, which is an investigational product for the treatment of rhabdomyosarcoma. Rhabdomyosarcoma is a life-threatening form of pediatric cancer that affects children.

Immix Biopharma’s cancer treatment is currently undergoing a Phase 1b/2a clinical trial. With the RPD designation from the FDA, the company can fast track its treatment for review. That could include a Priority Review Voucher if the FDA approves a New Drug Application for IMX-110.

Ilya Rachman, M.D., PhD., CEO of Immix Biopharma, said the following about the FDA news sending IMMX stock higher today.

‘We are encouraged by our Phase 1b/2a clinical data in soft tissue sarcoma. IMX-110 is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment, severing the critical lifelines between the tumor and its metabolic and structural support. We believe our SMARxT platform generating Tissue-Specific Therapeutics represents a distinct alternative to the traditional ‘single target, single mutation’ development model.”

The positive FDA news for Monday also has IMMX stock experiencing heavy trading. As of this writing, more than 81 million shares of the company’s stock have changed hands. That’s an impressive jump over the daily average trading volume of 1.2 million shares.

IMMX stock is up 118% as of Monday morning.

Investors seeking more of the latest stock market news are in the right place!

We’ve got all the most recent news traders need to know about. That includes this morning’s biggest pre-market stock movers, what’s going on with Naked Brand (NASDAQ:NAKD), as well as the latest concerning Novavax (NASDAQ:NVAX). You can find all of that at the links below!

More Recent Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks. 

Read More:Penny Stocks — How to Profit Without Getting Scammed

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC